Lilly set for strong quarter after Novo profit warning

Novo Nordisk cut its full-year sales and profit guidance, leading to a $70 billion market value loss, citing increased competition including from compounded versions of its obesity drug Wegovy. This development positions rival Eli Lilly favorably, given its Zepbound currently leads the U.S. obesity market with less exposure to compounding issues. However, Lilly's shares still fell nearly 5% amid investor concerns about potential aggressive price cuts from Novo or a broader slowdown in the obesity market, making its upcoming earnings report critical for market clarity and future outlook.

Analysis

Novo Nordisk's profit warning and subsequent $70 billion market value loss have materially altered the competitive landscape of the obesity drug market, creating a perceived advantage for rival Eli Lilly. Novo's guidance cut was attributed to lower U.S. growth and significant competition from compounded versions of its drugs, a pressure point that has affected Eli Lilly to a lesser extent. This dynamic reinforces Lilly's strong market position, where its drug Zepbound already holds nearly 60% of the U.S. obesity market and is capturing approximately two-thirds of new patients. Further bolstering Lilly's case is the superior efficacy demonstrated in a head-to-head trial, where Zepbound achieved 20.2% weight loss versus 13.7% for Novo's Wegovy. Despite these fundamental strengths, Eli Lilly's stock fell nearly 5%, reflecting investor anxiety that Novo's weakness could trigger aggressive price cuts or signal a broader slowdown in the obesity market. Consequently, Lilly's upcoming earnings report, with expectations of $14.71 billion in quarterly revenue, has become a critical catalyst to either validate its resilience or confirm market-wide headwinds.

Key Decisions for Investors

• Eli Lilly's upcoming earnings report is a pivotal event; investors should scrutinize whether the company reaffirms or raises its full-year profit outlook to counter contagion fears stemming from Novo's guidance cut.
• Monitor for any strategic pricing actions from Novo Nordisk, as aggressive discounting on Wegovy could initiate a price war that would compress margins across the entire sector, impacting Lilly's profitability despite its market share leadership.
• Given the performance divergence where Novo's shares have fallen over 40% YTD versus a marginal decline for Lilly, investors should assess if Lilly's stronger competitive footing justifies a continued premium or a strategic overweight position.
• Look for management commentary on the pipeline, specifically any updates on the planned regulatory submission for the oral obesity drug orforglipron, as progress could serve as a significant long-term growth catalyst.